【作者】 林存智； 朱新红； 窦泽燕； 牛娟娟； 刘欣；

【Author】 QINGDAO CHEST HOSPITAL ,896 CHONGQING ZHONG ROAD ,QINGDAO (266043), LIN CUNZHI, ZHU XINHONG,DOU ZEYAN ,ET AL

【机构】 青岛市胸科医院；

【摘要】 目的分析初治和多药耐药结核病患者经过2个月强化期治疗前后,外周血中细胞因子干扰素Ⅱ型(IFN—γ)和白细胞介素-12(IL-12)的变化,判断患者免疫功能恢复情况。方法随机选择70例结核病患者. 初治和多药耐药结核病患者各35例,应用酶联免疫吸附试验(ELISA)分别于治疗前、2个月强化期治疗后检测外周血中IFN—γ和IL-12的变化,同时设健康对照组。结果初治组患者经过2个月的强化期治疗后,外周血中IFN—γ和IL-12的含量恢复到健康人水平;而多药耐药结核病患者外周血中IFN—γ和IL-12的含量仍未恢复到正常水平。结论经过两个月的强化期治疗后,初治组患者的免疫功能恢复到正常人水平,而多药耐药组病人的免疫功能未恢复到正常水平,需给予免疫增强剂治疗。更多还原

【Abstract】 Objective: To analyze the changes of IFN- γ and IL-12 in patient/s peripheral blood with pulmonary tuberculosis after enrichment stage for two months, and to judge the functional recovery of immunology. Method: 70cascs with pulmonary tuberculosis were selected at random, and divided into two group: initial group and multidrug resistance group(MDR), and detected the changes of IFN- γ and IL-12 in patient/s peripheral blood pretherapy and post-therapy tor two months by ELISA.At the same time ,we set up control group. Result: The IFN- γ and IL-12 in initial group after two months treatment reach to that of control group, while in MDR group they still to remain unnormal level. Conclusion: The patient/s immunologic function in initial group recovery well, while the MDR patients remain low level. So to supply immunoenhancer for them.更多还原